EXACT SCIENCES CORP (1EXAS.MI) Stock Fundamental Analysis
Europe - Euronext Milan - BIT:1EXAS - US30063P1057 - Common Stock
49.355 EUR
+3.73 (+8.18%)
1EXAS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 75 industry peers in the Biotechnology industry. 1EXAS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, 1EXAS is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year 1EXAS has reported negative net income.
1EXAS had a positive operating cash flow in the past year.
1EXAS had negative earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: 1EXAS reported negative operating cash flow in multiple years.
1.2 Ratios
With a Return On Assets value of -17.34%, 1EXAS perfoms like the industry average, outperforming 56.79% of the companies in the same industry.
With a Return On Equity value of -40.71%, 1EXAS perfoms like the industry average, outperforming 59.26% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.34% | ||
| ROE | -40.71% | ||
| ROIC | N/A |
ROA(3y)-10.17%
ROA(5y)-11.23%
ROE(3y)-23.27%
ROE(5y)-24.85%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of 1EXAS (68.19%) is comparable to the rest of the industry.
In the last couple of years the Gross Margin of 1EXAS has declined.
1EXAS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.19% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.06%
GM growth 5Y-1.57%
2. Health
2.1 Basic Checks
1EXAS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for 1EXAS has been increased compared to 1 year ago.
Compared to 5 years ago, 1EXAS has more shares outstanding
Compared to 1 year ago, 1EXAS has a worse debt to assets ratio.
2.2 Solvency
1EXAS has an Altman-Z score of 1.48. This is a bad value and indicates that 1EXAS is not financially healthy and even has some risk of bankruptcy.
1EXAS has a Altman-Z score (1.48) which is comparable to the rest of the industry.
The Debt to FCF ratio of 1EXAS is 18.77, which is on the high side as it means it would take 1EXAS, 18.77 years of fcf income to pay off all of its debts.
1EXAS has a better Debt to FCF ratio (18.77) than 75.31% of its industry peers.
1EXAS has a Debt/Equity ratio of 0.94. This is a neutral value indicating 1EXAS is somewhat dependend on debt financing.
1EXAS's Debt to Equity ratio of 0.94 is on the low side compared to the rest of the industry. 1EXAS is outperformed by 61.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.94 | ||
| Debt/FCF | 18.77 | ||
| Altman-Z | 1.48 |
ROIC/WACCN/A
WACC8.4%
2.3 Liquidity
A Current Ratio of 2.89 indicates that 1EXAS has no problem at all paying its short term obligations.
1EXAS has a Current ratio (2.89) which is comparable to the rest of the industry.
A Quick Ratio of 2.56 indicates that 1EXAS has no problem at all paying its short term obligations.
With a Quick ratio value of 2.56, 1EXAS perfoms like the industry average, outperforming 58.02% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.89 | ||
| Quick Ratio | 2.56 |
3. Growth
3.1 Past
The earnings per share for 1EXAS have decreased strongly by -465.63% in the last year.
1EXAS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 12.56%.
1EXAS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 25.78% yearly.
EPS 1Y (TTM)-465.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88.89%
Revenue 1Y (TTM)12.56%
Revenue growth 3Y16.01%
Revenue growth 5Y25.78%
Sales Q2Q%15.99%
3.2 Future
The Earnings Per Share is expected to grow by 20.32% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 10.08% on average over the next years. This is quite good.
EPS Next Y88.82%
EPS Next 2Y44.25%
EPS Next 3Y30.34%
EPS Next 5Y20.32%
Revenue Next Year14.88%
Revenue Next 2Y13.51%
Revenue Next 3Y13.05%
Revenue Next 5Y10.08%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
1EXAS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 128.04 indicates a quite expensive valuation of 1EXAS.
1EXAS's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. 1EXAS is cheaper than 75.31% of the companies in the same industry.
1EXAS is valuated expensively when we compare the Price/Forward Earnings ratio to 34.46, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 128.04 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, 1EXAS is valued a bit cheaper than 70.37% of the companies in the same industry.
1EXAS's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. 1EXAS is cheaper than 79.01% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 87.58 | ||
| EV/EBITDA | 183.48 |
4.3 Compensation for Growth
1EXAS's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as 1EXAS's earnings are expected to grow with 30.34% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y44.25%
EPS Next 3Y30.34%
5. Dividend
5.1 Amount
1EXAS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIT:1EXAS (10/7/2025, 7:00:00 PM)
49.355
+3.73 (+8.18%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners95.27%
Inst Owner ChangeN/A
Ins Owners0.87%
Ins Owner ChangeN/A
Market Cap9.34B
Revenue(TTM)2.94B
Net Income(TTM)-1.01B
Analysts85.81
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)27.73%
Min EPS beat(2)-39.07%
Max EPS beat(2)94.53%
EPS beat(4)2
Avg EPS beat(4)-333.88%
Min EPS beat(4)-1391.93%
Max EPS beat(4)94.53%
EPS beat(8)5
Avg EPS beat(8)-143.38%
EPS beat(12)9
Avg EPS beat(12)-87.39%
EPS beat(16)11
Avg EPS beat(16)-65.6%
Revenue beat(2)2
Avg Revenue beat(2)1.64%
Min Revenue beat(2)0.62%
Max Revenue beat(2)2.65%
Revenue beat(4)2
Avg Revenue beat(4)-0.05%
Min Revenue beat(4)-3.19%
Max Revenue beat(4)2.65%
Revenue beat(8)2
Avg Revenue beat(8)-0.26%
Revenue beat(12)6
Avg Revenue beat(12)1.07%
Revenue beat(16)10
Avg Revenue beat(16)1.66%
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)-33.47%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-4.32%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)-0.01%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 128.04 | ||
| P/S | 3.71 | ||
| P/FCF | 87.58 | ||
| P/OCF | 35.71 | ||
| P/B | 4.42 | ||
| P/tB | N/A | ||
| EV/EBITDA | 183.48 |
EPS(TTM)-4.65
EYN/A
EPS(NY)0.39
Fwd EY0.78%
FCF(TTM)0.56
FCFY1.14%
OCF(TTM)1.38
OCFY2.8%
SpS13.29
BVpS11.17
TBVpS-3.91
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.34% | ||
| ROE | -40.71% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.19% | ||
| FCFM | 4.24% |
ROA(3y)-10.17%
ROA(5y)-11.23%
ROE(3y)-23.27%
ROE(5y)-24.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.06%
GM growth 5Y-1.57%
F-Score4
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.94 | ||
| Debt/FCF | 18.77 | ||
| Debt/EBITDA | 35.11 | ||
| Cap/Depr | 83.3% | ||
| Cap/Sales | 6.16% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 459.82% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.89 | ||
| Quick Ratio | 2.56 | ||
| Altman-Z | 1.48 |
F-Score4
WACC8.4%
ROIC/WACCN/A
Cap/Depr(3y)84.38%
Cap/Depr(5y)130.41%
Cap/Sales(3y)7.28%
Cap/Sales(5y)12.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-465.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88.89%
EPS Next Y88.82%
EPS Next 2Y44.25%
EPS Next 3Y30.34%
EPS Next 5Y20.32%
Revenue 1Y (TTM)12.56%
Revenue growth 3Y16.01%
Revenue growth 5Y25.78%
Sales Q2Q%15.99%
Revenue Next Year14.88%
Revenue Next 2Y13.51%
Revenue Next 3Y13.05%
Revenue Next 5Y10.08%
EBIT growth 1Y16.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year331.6%
EBIT Next 3Y83.93%
EBIT Next 5Y52.64%
FCF growth 1Y214.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y316.93%
OCF growth 3YN/A
OCF growth 5YN/A
EXACT SCIENCES CORP / 1EXAS.MI FAQ
What is the fundamental rating for 1EXAS stock?
ChartMill assigns a fundamental rating of 3 / 10 to 1EXAS.MI.
Can you provide the valuation status for EXACT SCIENCES CORP?
ChartMill assigns a valuation rating of 3 / 10 to EXACT SCIENCES CORP (1EXAS.MI). This can be considered as Overvalued.
Can you provide the profitability details for EXACT SCIENCES CORP?
EXACT SCIENCES CORP (1EXAS.MI) has a profitability rating of 2 / 10.
How financially healthy is EXACT SCIENCES CORP?
The financial health rating of EXACT SCIENCES CORP (1EXAS.MI) is 4 / 10.
What is the expected EPS growth for EXACT SCIENCES CORP (1EXAS.MI) stock?
The Earnings per Share (EPS) of EXACT SCIENCES CORP (1EXAS.MI) is expected to grow by 88.82% in the next year.